Company profile
New Leaf Ventures Inc
OTC: NLVVF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#828 of 1,418 Healthcare companies by revenue27th-percentile growth
EA Score
——FH —DQ —GM —SS 21
v0.1 · 5/100 weight · pillars only
↑ Altman-Z, net margin · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
-42.5%
Net income (FY)
-$2.7M
Employees
12
as of 2026-08-30
Market cap
$3.0k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.5M2.0M CAD2022
Net income-$2.7M-3.5M CAD2022
Operating income-$3.0M-3.9M CAD2022
Total assets$1.7M2.3M CAD2022
Liabilities$2.7M3.6M CAD2022
Equity-$999.9k-1.4M CAD2022
Revenue trend
FY2018 – FY2022 · USD
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is New Leaf Ventures Inc’s revenue?
New Leaf Ventures Inc booked $1.5M in FY2022 revenue, contracting 23% year over year — slower than 73% of Healthcare companies we track, at a -177.7% net margin.
Peers · Healthcare
Celldex Therapeutics, Inc.58COrthometrix, Inc.——Molecule Holdings Inc.——St. Joseph, Inc.67BStatera Biopharma, Inc.——Xsovt Brands, Inc.——Key facts
CEORobert Colwell
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: NLVVF
Employees12
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.